Content about Voriconazole

December 17, 2013

Greenstone has launched a version of a drug used to treat fungal infections, the company said.

PEAPACK, N.J. — Greenstone has launched a version of a drug used to treat fungal infections, the company said.

Greenstone, the generics subsidiary of Pfizer, announced the introduction of voriconazole for oral suspension, an authorized generic version of Pfizer's Vfend. Authorized generics are branded drugs sold at a discount under their generic names.

Greenstone is selling the drug in the 40 mg-per-milliliter strength. Vfend had sales of about $17.1 million during the 12-month period that ended in June, according to IMS Health.

 

September 30, 2013

Mylan has launched the first generic version of a drug used to treat fungal infections, the company said Monday.

PITTSBURGH — Mylan has launched the first generic version of a drug used to treat fungal infections, the company said Monday.

The drug maker announced the launch of voriconazole for oral suspension in the 40-mg-per-mL strength. The drug is the first generic version of Pfizer's Vfend, and as the first company to receive approval for a generic version, Mylan has 180 days in which to compete exclusively against Pfizer's product. The drug is used to treat invasive fungal infections.

December 19, 2011

The Food and Drug Administration has approved a drug made by Sandoz for treating yeast and other fungal infections.

PRINCETON, N.J. — The Food and Drug Administration has approved a drug made by Sandoz for treating yeast and other fungal infections.

Sandoz announced Monday the approval of voriconazole tablets in the 50-mg and 200-mg strengths, a generic version of Pfizer's Vfend.

Branded and generic versions of the drug had sales of about $189 million during the 12-month period ended in October, according to IMS Health.

 

February 15, 2011

Mylan has launched a generic drug for fungal infections, the company said Tuesday.

PITTSBURGH — Mylan has launched a generic drug for fungal infections, the company said Tuesday.

Mylan announced the launch, through subsidiary Mylan Pharmaceuticals, of voriconazole tablets in the 50-mg and 200-mg strengths. The drug is a triazole antifungal agent.

The tablets are a generic version of Pfizer’s Vfend, which had sales of $186 million in 2010, according to IMS Health. Mylan launched its version of the drug under a settlement with Pfizer.